Stevenage Bioscience Catalyst opens the Lab Hotel, with first residents announced as Oppilotech, Exogene and Immtune Therapies
Published on 23 Nov 2020
Achilles Therapeutics Raises £52.7 Million in an Oversubscribed Series C Financing to Further Advance the Development of Personalised T cell Therapies to Treat Solid Tumours
Published on 19 Nov 2020
Myricx Pharma Launches with £4.5M Financing to Progress its Novel NMT inhibitors in Cancer
Published on 16 Nov 2020
TCR² Therapeutics Announces Partnership With Elevatebio To Expand Tc-210 Manufacturing Capacity
Published on 11 Nov 2020
Gyroscope Therapeutics Announces First Patient Dosed in Phase II HORIZON Trial Evaluating Investigational Gene Therapy, GT005, in People with Dry Age-Related Macular Degeneration
Published on 11 Nov 2020
New report shows 10% of UK’s top female BioBusiness talent is based at Stevenage Bioscience Catalyst
Published on 9 Nov 2020
Celebrating the achievements of the Advanced Therapies Apprenticeship Community
Published on 3 Nov 2020
Freeline appoints Mark Baldry as Chief Commercial Officer
Published on 3 Nov 2020
Gyroscope Therapeutics Announces First Patient Received Investigational Gene Therapy GT005 Via Orbit Subretinal Delivery System in Ongoing Phase I/II FOCUS Trial
Published on 3 Nov 2020

Peptinnovate announces change of name to Immune Regulation, strengthening of the Board and successful fundraise

Read the article
The appointment of these three experienced industry executives will bring valuable insight and resource to our Board and executive team. With their skills in immunology, clinical therapeutic development and strategy we have the expertise to advance our clinical programmes and look forward to the next stage of our progress.
Prof. Clive Page
Chairman of Immune Regulation
CGT Catapult appoints two new Board members
Published on 27 Oct 2020
Stevenage named High Potential Opportunity zone for Cell and Gene Therapy
Published on 12 Oct 2020
Stevenage Bioscience Catalyst opens Spark Building to support Cell and Gene scale-up
Published on 12 Oct 2020
Press Release: CGT Catapult appoints Dr Nick Johnson as Chief Strategy and Impact Officer
Published on 6 Oct 2020
LifeArc and UK government’s Future Fund provide £3.0m in funding to Avvinity Therapeutics to drive development of new cancer therapies
Published on 23 Sep 2020
Immune Regulation Limited raises £40.6 million / $53.4 million Series B Equity Financing
Published on 21 Sep 2020
AKL Research & Development’s novel osteoarthritis medicine APPA begins Phase II trial with partner Nordic Bioscience Clinical Development
Published on 18 Sep 2020
CombiGene and CGT Catapult collaboration completes development of quality control analytical assays for clinical production of CombiGene’s AAV-based gene therapy for the treatment of epilepsy
Published on 17 Sep 2020
Gyroscope Therapeutics Announces FDA Clearance For Orbit Subretinal Delivery System
Published on 27 Aug 2020
ReViral Raises $44 Million in Series C Financing
Published on 25 Aug 2020
Gyroscope Therapeutics Announces Initiation Of Phase II Programme Evaluating Its Investigational Gene Therapy, GT005, for Dry Age-related Macular Degeneration
Published on 25 Aug 2020
Stevenage Bioscience Catalyst announces Professor Jackie Hunter as new Chair
Published on 17 Aug 2020

Copyright © 2020 Stevenage Bioscience Catalyst

Designed and built by Onespacemedia

We use cookies to improve our site experience. Press accept to agree to our Cookie Policy. If you decline, your information won’t be tracked when you visit this website. A single cookie will be used in your browser to remember your preference not to be tracked.